Funding:

Merck Sharp & Dohme Corp.

Description

The MS Center at EvergreenHealth is conducting a randomized, double-blind, placebo-controlled, cross-over trial to assess the safety, tolerability, and efficacy of suvorexant (Belsomra®) in treating insomnia in adults with multiple sclerosis (MS) and fatigue. This study will assess whether suvorexant (Belsomra®) is more effective than placebo in treating insomnia and fatigue in people with MS. Enrolled patients will come to the study site for 4 visits (45 – 90 minutes each) during the study. Patients will also have 3 or more phone conversations with a study coordinator.